Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review
Waqar Waheed,1 Eric Newman,1 Marwa Aboukhatwa,2 Maryam Moin,3 Rup Tandan1 1Department of Neurological Sciences, The University of Vermont and the University of Vermont Medical Center, Burlington, VT, USA; 2Pharmacotherapy Department, University of Vermont Medical Center, Burlington, VT, USA; 3Depart...
Main Authors: | Waheed W, Newman E, Aboukhatwa M, Moin M, Tandan R |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-07-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/practical-management-for-use-of-eculizumab-in-the-treatment-of-severe--peer-reviewed-fulltext-article-TCRM |
Similar Items
-
Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum]
by: Waheed W, et al.
Published: (2022-08-01) -
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
by: Jonathan P. R. Monteleone, et al.
Published: (2021-11-01) -
Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report
by: Tuan Vu, et al.
Published: (2021-02-01) -
Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients
by: Eleonora Lekova, et al.
Published: (2022-09-01) -
Complement Inhibitor Therapy for Myasthenia Gravis
by: Khaled Albazli, et al.
Published: (2020-06-01)